Maxcyte (MXCT) Operating Income (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Income data on file, last reported at -$6.2 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$6.2 million, up 49.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 million (up 62.08% YoY), and the FY2025 annual result was -$9.4 million, down 9.19% from the prior year.
• Operating Income slipped to -$6.2 million in Q1 2026 per MXCT's latest filing, from $31.3 million in the prior quarter.
• Over five years, Operating Income peaked at $31.3 million in Q4 2025 and troughed at -$14.2 million in Q2 2025.
• A 5-year average of -$5.9 million and a median of -$12.0 million in 2024 frame the typical range for Operating Income.
• The sharpest annual moves came in 2023 and 2024: Operating Income slumped 216.85% in 2023, then surged 467.01% in 2024.
• A 5-year view of Operating Income shows it stood at -$6.8 million in 2022, then fell by 19.93% to -$8.1 million in 2023, then surged by 467.01% to $29.7 million in 2024, then advanced by 5.34% to $31.3 million in 2025, then slumped by 119.76% to -$6.2 million in 2026.
• Business Quant data shows MXCT's Operating Income at -$6.2 million in Q1 2026, $31.3 million in Q4 2025, and -$14.1 million in Q3 2025.